Beviprex
- Beviprex inhaler is formulated to address chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
- Combines Glycopyrronium Bromide, a long-acting muscarinic antagonist (LAMA), and Formoterol Fumarate, a long-acting β2-adrenergic agonist (LABA), for effective airway dilation.
- Administered via inhalation, it relaxes smooth muscles and stimulates adenylyl cyclase activity to improve breathing.
- Suitable for adults, dosing involves 2 puffs twice daily, with considerations for severe renal impairment.
- Contraindications include asthma without long-term control medication use and hypersensitivity to its components.
Onriva Trio
- Introducing Onriva Trio: an innovative inhalation powder for adults with asthma.
- Combines Indacaterol Acetate, Glycopyrronium Bromide, and Mometasone Furoate for comprehensive treatment.
- Provides bronchodilation and anti-inflammatory benefits directly to the lungs.
- Once-daily administration via inhalation device for ease of use.
- Designed to reduce asthma exacerbations and enhance respiratory function effectively.
